Jcr Pharmaceuticals
JCR Pharmaceuticals Co., Ltd., commonly referred to as JCR Pharma, is a leading biopharmaceutical company headquartered in Japan. Established in 2003, the company has made significant strides in the development of innovative therapies, particularly in the fields of rare diseases and regenerative medicine. With a strong focus on enzyme replacement therapies and gene therapies, JCR Pharma is renowned for its unique products that address unmet medical needs. The company operates primarily in Japan, with expanding influence in international markets. Notable achievements include the successful launch of its flagship products, which have positioned JCR Pharma as a key player in the biopharmaceutical industry. Through its commitment to research and development, JCR Pharmaceuticals continues to enhance the quality of life for patients worldwide.
DitchCarbon Score
How does Jcr Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jcr Pharmaceuticals's score of 32 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jcr Pharmaceuticals's reported carbon emissions
In 2021, JCR Pharmaceuticals reported total greenhouse gas emissions of approximately 85,536,000 kg CO2e. This figure includes Scope 1 emissions of about 2,232,000 kg CO2e, Scope 2 emissions of approximately 5,136,000 kg CO2e (market-based), and significant Scope 3 emissions totalling around 78,168,000 kg CO2e. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (about 70,232,000 kg CO2e) and capital goods (approximately 3,501,000 kg CO2e). JCR Pharmaceuticals is committed to addressing climate change by aligning its strategies with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD). The company has set near-term targets to calculate and manage greenhouse gas emissions across its entire supply chain, specifically focusing on Scope 1 and Scope 2 emissions. These initiatives are set to commence in 2023 and conclude in 2025, reflecting JCR's dedication to transparency and proactive climate risk management.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | |
|---|---|
| Scope 1 | 2,232,000 |
| Scope 2 | 5,136,000 |
| Scope 3 | 78,168,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jcr Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
